Mobocertinib Gets Priority Review for EGFR Exon20 Insertion+ Metastatic NSCLC
Mobocertinib is an investigational, first-in-class, oral tyrosine kinase inhibitor designed to selectively target EGFR Exon20 insertion mutations.
Respiratory and Thoracic Cancers
Changes in Cancer Incidence, Deaths Expected by 2040
Most common cancers will be breast, melanoma, and lung, while most common cause of cancer-related death will remain lung
Tislelizumab Plus Chemo Slows Advanced Squamous NSCLC
Progression-free survival significantly longer with tislelizumab plus chemotherapy versus chemotherapy alone
FDA-Approved VEGFR Tyrosine Kinase Inhibitors Ranked by Cardiotoxic Potential
Lenvatinib was associated with the most significant probability of producing all grades of cardiovascular injury and hypertension.
Indications Withdrawn as FDA Evaluates Several Accelerated Approvals
To prove clinical benefit, the FDA requires manufacturers to conduct confirmatory trials, also known as a phase 4 studies.
Libtayo Cleared for Frontline Use in Advanced NSCLC With High PD-L1 Expression
The approval is based on data from the randomized, open-label phase 3 EMPOWER-Lung1 trial.
Tepmetko Gets Accelerated Approval for Metastatic NSCLC
The approval was based on data from the multicenter, single-arm, open-label, multicohort phase 2 VISION study.
No Added Benefit With Pembrolizumab Combo vs Monotherapy for Metastic NSCLC
Results showed the median OS was 21.4 months in the pembrolizumab plus ipilimumab arm compared with 21.9 months in the pembrolizumab monotherapy arm.
Combined Modalities Improve Survival in Stage III Inoperable NSCLC
This study tested the efficacy of singular and combined treatment modalities on survival in patients with inoperable, locally advanced non-small cell lung cancer (≥70 years).
Potential Med Errors Prompt FDA Action on Vinca Alkaloid Labeling
Chemotherapy agents such as vincristine sulfate injection, vinblastine sulfate injection, and vinorelbine tartrate injection should only be prepared in IV infusion bags.
